Trials with medicinal products
A5481092 palbociclib (relapsed or refractory Ewing sarcoma) Clinical study comparing the efficacy and safety of palbociclib in combination with chemotherapy versus chemotherapy alone in children, adolescents and young adults with relapsed or refractory Ewing sarcoma - open for inclusion
CRISP (tumors with ALK/MET/ROS1 abnormalities) Clinical study of the safety and efficacy of the drug crizotinib in children, either alone or in combination with other drugs - open for inclusion
ESMART (different tumor types) Clinical study in children with cancer into the safety and efficacy of drugs matching a specific DNA alteration in the tumor - open for inclusion
INFORM2 NivEnt (various solid tumors) Clinical study with nivolumab and entinostat in children and young adults with refractory cancer - open for inclusion
LOXO-TRK-15003 (solid/CNS tumors) Clinical study of the safety and efficacy of the drug LOXO-101 (larotrectinib) in children with advanced solid tumors or primary central nervous system tumors - closed for inclusion
Ponatinib INCB084344 (leukemia/solid tumors) Clinical study of the safety and efficacy of ponatinib for the treatment of different types of leukemia or solid tumors in children - open for inclusion
Other trials
DRUG Access protocol (solid tumors) A national protocol to facilitate access to new anti-cancer drugs and collect data from targeted anti-cancer drugs not yet eligible for reimbursement - open for inclusion
FOCUS Clinical study to optimize dosing of fluconazole in children for the prevention or treatment of invasive fungal infections - open for inclusion
PINOCCHIO (multiple types of cancer) Clinical study in children on the metabolism, distribution and excretion of chemotherapy in the body, also called pharmacokinetics - open for inclusion
Tumor donation in Childhood Cancer patients This study is designed to enable post-mortem tumor donation in children that die from all different types of pediatric solid and brain tumors, to enable research on end-stage disease -open for inclusion